LEARNING OBJECTIVES
After participating in this activity, the reader should be able to: 1. Identify the most commonly encountered post-operative complications after pancreatic resection and explain the clinical benefits of pasireotide. 2. Compare total direct costs between patients treated with placebo vs. pasireotide and patients who developed post-operative pancreatic fistula vs. those who did not. Postoperative pancreatic fistula (POPF) is a major contributor to the significant morbidity and mortality associated with pancreatic resection. Even among high-volume centers, POPF has a reported rate of 10% to 35%. [1] [2] [3] [4] [5] [6] [7] POPF is characterized by the leakage of pancreatic exocrine secretions, which can be inhibited and reduced in vivo by somatostatin, a peptide hormone secreted from pancreatic delta cells. Over the past several decades, a variety of somatostatin analogues have been investigated as prophylactic agents to prevent POPF. The results of these trials however have been mixed, and thus, routine somatostatin analogue treatment has not become the standard of care following pancreatic resection. [8] [9] [10] [11] [12] Pasireotide, the most recently derived somatostatin analogue, has garnered significant interest in the prevention of POPF, as it has shown a broader binding affinity and superior pharmacokinetic profile than other somatostatin analogues. Our institution recently published the results of a randomized, double-blind, placebo-controlled trial of perioperative subcutaneous pasireotide in 300 patients who had undergone pancreatic resection. 13 Patients who received pasireotide had a significantly lower incidence of a grade 3 or higher POPF, leak, or abscess compared with those who received placebo. This difference in the occurrence of POPF remained significant in subgroup analysis by type of pancreatic resection, presence or absence of pancreatic duct dilation at the site of transection, and surgical drain placement. In addition, the overall rate of pancreatic complications was lower for patients in the pasireotide study group, and patients who received pasireotide experienced a decreased hospital readmission rate.
The economic ramifications of POPF can be significant. [14] [15] [16] As cost assessments have become an increasingly utilized outcomes measure, it is imperative to evaluate the cost-effectiveness of pasireotide from this recent study. The aim of the current study was to determine the costs of clinically significant POPF and to evaluate the cost-effectiveness of routine pasireotide use for patients undergoing pancreatic resection.
METHODS
Between November 2009 through June 2013, patients were enrolled in a phase 3, single-center, randomized, double-blind, placebo-controlled trial evaluating the efficacy of pasireotide in reducing the incidence of POPF in pancreatic resections (ClinicalTrials.gov number, NCT00994110). Pancreatoduodenectomy From the or distal pancreatectomy was performed following standard surgical principles and guidelines, but the particular technique differed according to the patient's needs and the surgeon's preferences. 13 Patients were randomly assigned in a 1 : 1 ratio to receive 900 mg of subcutaneous pasireotide or placebo twice a day, beginning preoperatively on the day of surgery, and continuing for 7 days postoperatively for a total of 14 doses. Randomization was performed using permuted blocks of random size to stratify group assignments according to type of pancreatic resection and presence or absence of pancreatic duct dilation. All members of the clinical team were unaware of the group assignments. Details of the patients' presenting characteristics, the intraoperative and perioperative period, and the 90-day postoperative follow-up period were prospectively collected. The primary endpoint of this trial was the development of a grade 3 or higher pancreatic fistula, leak, or abscess at 60 days postoperatively, as defined by the Memorial Sloan-Kettering Cancer Center (MSKCC) Surgical Secondary Events System. 13 Secondary endpoints included the overall rate of all pancreatic complications and the rate of grade B or grade C pancreatic fistula as defined by the International Study Group on Pancreatic Fistula (ISGPF). 17 Itemized hospital costs from institutional accounting data were used to estimate total medical direct costs (costs of specific goods and services, including physician services) for the 300 patients enrolled in this trial. Total direct costs were estimated from the date of the index admission for surgery through 90 days postoperatively. All direct costs were inflation adjusted to 2013 US dollars using the Consumer Price Index-All Items. In an effort to yield generalizable estimates, institution-specific costs were converted to reflect 2013 Medicare reimbursement levels.
In more detail, a total direct cost estimate for all patients was calculated by visit type (index admissions, readmissions, or outpatient visits). A total Medicare reimbursement amount for all patients was then calculated by visit type using diagnosis-related group (DRG) level reimbursements for inpatient admissions and resource-based relative value scale-based reimbursement for outpatient visits, less any hospital-specific add-on payments (Insert reference: Services CfMaM. 1st Quarter 2012 Values for Hospital Outpatient Prospective Payment System Payment Amounts (Addendum B). http://www.cms.gov/Medi care/Medicare-Fee-for-ServicePayment/HospitalOutpatientPPS/Addendum-A-and-Addendum-BUpdates.html. Accessed September, 2014.). A reimbursement-to-cost ratio was calculated for each visit type based on these estimates. Costs of each individual item recorded in the institutional cost-accounting database were then multiplied by the relevant reimbursement to cost ratio (one for the initial inpatient admission, one for all outpatient visits, and one for readmissions) to estimate the amount that would be reimbursed by Medicare. Hereafter these cost estimates are referred to as Medicare proportional dollars (MP$). For example, a hospitalspecific outpatient visit that cost $100 would be reported as MP$50 if the reimbursement to cost ratio for all outpatient visits was estimated at 0.50. This approach is similar to the method Medicare uses to determine reimbursement levels for hospital care 18 , a process that involves hospitals reporting costs using bottom up accounting and their own cost to charge multipliers. This method has been used previously to normalize hospital-specific cost estimates. 19 The cost of pasireotide was based on Medicare reimbursement for the 900 mg dosing formulation using a reimbursement level of 95% of the average wholesale price (AWP) in 2013 ($287.68 per 900 mg). 20 Therefore, the estimated cost of 1 dose of pasireotide in 2013 Medicare proportional dollars was MP$273.30. The total cost of the study drug was calculated on the basis of the number of doses each patient received. This amount was added to the total direct cost for each patient.
All cost estimates were rounded to the nearest hundred dollars. Data analysis was performed using IBM SPSS version 22 and Microsoft Excel 2007. Two-sample t test was used to evaluate for difference in means between comparison groups. A P value <0.05 was considered significant.
RESULTS
Three hundred patients were included for analysis. One hundred fifty-two patients were randomized to receive pasireotide and 148 patients to receive placebo. In the pasireotide group, 111 patients underwent pancreaticoduodenectomy and 41 patients underwent distal pancreatectomy. The median length of stay (LOS) for the index admission was 7 days (range 4 to 27 days) for patients who underwent pancreaticoduodenectomy and 5 days (range 4 to 9 days) for those who underwent distal pancreatectomy. In the placebo group, 109 patients underwent pancreaticoduodenectomy with median LOS of 7 days (range 4 to 72 days), and 39 underwent distal pancreatectomy with median LOS of 7 days (range 4 to 13 days). Patient characteristics, operative details, and postoperative outcomes are presented in Table 1 .
The primary endpoint was met in 45 patients (15.0%). In the pasireotide group, 14 of 152 patients (9.2%) met the primary endpoint, and 31 of 148 patients (20.9%) in the placebo group met the primary endpoint (P ¼ 0.006). The absolute risk reduction with pasireotide administration was 11.7%, with the number needed to treat in order to prevent 1 event being 8. A significant risk reduction was also seen during subgroup analysis by type of resection (pancreaticoduodenectomy or distal pancreatectomy), presence or absence of duct dilation, and surgical drain placement. Grade B and C fistula rates as defined by the ISGPF were also recorded and occurred in 37 patients (12.3%). In the pasireotide group, 12 patients (7.9%) developed a grade B POPF, and none developed a grade C POPF. In the placebo group, 20 patients (13.5%) developed a grade B POPF and 5 (3.4%) developed a grade C POPF (P ¼ 0.02 between pasireotide and placebo group). Overall, 54 patients (18.0%) developed any grade of pancreatic complication, with 17 patients (11.2%) from the pasireotide group and 37 patients (25.0%) from the placebo group (P ¼ 0.002) experiencing these events. Readmission occurred in 29 of 45 patients (64%) with clinically significant POPF and 40 of 255 (16%) patients without clinically significant POPF (P < 0.001). The readmission rate was also higher in the placebo group (43/148, 29%) than the pasireotide group (26/152, 17%) (P ¼ 0.02). The mean total direct cost estimate for all 300 patients from the index admission to 90 days postoperatively was MP$23,400 (range MP$8,000-MP$202,500). The mean total direct cost estimate in the pasireotide group was MP$22,800 (range MP$10,400-MP$80,300). The placebo group experienced a higher mean total direct cost estimate of MP$23,900 (range MP$8,000-MP$202,500); however, this did not reach statistical significance (P ¼ 0.571) ( Table 2 ). The mean cost estimate of pasireotide treatment was MP$3,300 (range MP$300 -MP$3,800), and 76% of patients in the pasireotide group (115/152) received the complete 14-dose treatment regimen (Table 3 ). In the pasireotide group, 26 of the 37 patients were withdrawn from the study before completion of the 14-dose regimen due to nausea or vomiting that was temporally related to drug administration.
The mean total direct cost estimate was 2 times higher in the 45 patients who developed a grade 3 or higher pancreatic complication (mean MP$39,600, range MP$13,800 -MP$202,500) compared with the 255 patients who did not (mean MP$20,500, range MP$8,000-MP$62,900) (P ¼ 0.001). In the group of 45 patients who developed POPF, the 14 patients who received pasireotide also had a lower mean total cost estimate than the remaining 31 patients who received placebo (MP$32,100 vs MP$43,000, P ¼ 0.224).
DISCUSSION
Pancreatic resection continues to be a procedure that has significant morbidity and measurable mortality. 6, 21, 22 Pancreatic fistula, leak, and abscess (referred to in this study as pancreatic leak) are a group of complications related to the anastomosis (pancreaticoduodenectomy) or closure (distal pancreatectomy) of the pancreatic remnant. Pancreatic complications are presumed secondary to the leakage of pancreatic exocrine secretions and/or enteric contents, and are the most common major complication following pancreatectomy; they have been reported in 10% to 35% of patients who undergo resection. [1] [2] [3] [4] [5] [6] [7] We previously reported on the significance of this group of complications in a retrospective series of 908 patients who underwent pancreaticoduodenectomy or distal pancreatectomy at our institution over a 5-year time period (2000 to 2005). 16 Pancreatic leaks requiring prolonged use of surgical drains or additional interventions occurred in 158 of the 908 resected patients (17%) and reoperation was required in 26 patients (5%). The mortality rate of the 158 patients within this retrospective series who experienced leak was 5% (compared with a mortality rate of 2% in patients without pancreatic complications).
Numerous alterations in operative technique and management strategies have been trialed to reduce the prevalence of POPF with limited success and difficulties in reproducibility. [23] [24] [25] [26] [27] [28] The results from trials of other somatostatin analogues have been conflicting, and many surgeons have been hesitant to incorporate the routine use of somatostatin analogues into their practice. 2, 9, 12, 29, 30 Our recently published randomized clinical trial evaluated a new somatostatin analogue pasireotide, which has a much longer half-life than octreotide and a higher binding affinity for a wider range of somatostatin receptors. 31 This favorable pharmacokinetic profile may provide the rationale for the demonstrated benefit we found with pasireotide in reducing the occurrence of POPF.
POPFs also represent a significant economic burden. Gani et al 14 reported on the total hospital costs of 971 patients who underwent pancreatic resection at a high-volume academic center. The median total costs nearly doubled in those who developed a postoperative complication following pancreatic resection compared with those who did not. Enestvedt et al 15 reported similar results in a review of 144 patients undergoing pancreaticoduodenectomy in a network of communitybased hospitals composed of both low-and high-volume centers. The median cost was also nearly doubled for those with major complications, from $29,038 to $56,224. The development of pancreatic fistula was an independent predictor of increased total cost, and fistula alone accounted for a 1.3 times increase in the total cost, similar to the doubling in cost we report in our study in patients with POPF. Enestvedt et al 15 also found that postoperative complications tended to occur in clusters, and pancreatic fistula was generally associated with at least 4 other complications, further contributing to the accumulation of incurred costs. Complications after pancreatic resection represent an important area for quality improvement in order to maximize the value of care. An intervention, such as pasireotide that can dramatically reduce POPF rates, must be considered in order to improve the efficiency of resource use within our health care system. The primary goal is not only to reduce health care costs but also to improve the value of care.
In this study, we found that the routine use of pasireotide did not increase overall costs in pancreatic resection. The total directs costs estimates in patients who received pasireotide were actually lower than patients who received placebo (MP$22,800 vs MP$23,900); however, this was not statistically significant (P ¼ 0.571). This demonstrates that the use of pasireotide is a costeffective measure that can improve patient outcomes by reducing the incidence of POPF and the associated subsequent complications without increasing overall costs. The lack of a statistically significant cost difference between the pasireotide and placebo group is potentially a reflection of 1 of our study limitations in which the cost data during the 90-day postoperative follow-up period only included costs incurred at our institution. We were not able to obtain cost data whether a patient had chosen to seek care at an outside institution during this 90-day period. This is particularly applicable for patients who developed postoperative complications and had cause to seek additional, nonroutine postoperative care, and require. Using our institutional cost data, the pasireotide group had a lower, although not statistically significant, mean total cost estimate in Medicare proportional dollars than the placebo group. Potentially, if outside institutional cost data were incorporated, a statistically significant cost difference may emerge due to differences in the cost of postoperative care, as the placebo group did have significantly more occurrences of POPF as well as a higher percentage of readmission at our institution alone.
The strength of this study results from the fact that these data were derived from a randomized controlled trial, mitigating the effects of any potential bias, and ensuring the close monitoring and follow-up of all patients. Although this was a single-institution randomized control trial, we hope that the dramatic reduction in POPF we demonstrated with pasireotide use will encourage other institutions to participate in a larger, multi-institutional study for further validation. As with any single institution trial, our results are potentially affected by certain institutional practices, such as our use of surgical drains. Surgical drains are selectively place at our institution on the basis of the surgeon's perception of a high-risk gland, and any association between drain placement and POPF development is most likely a reflection of this high-risk nature, and not causative. In subgroup analysis of patients who had surgical drain placement, the rate of clinically significant POPF was significantly lower in the pasireotide group than the placebo group. As surgical drain placement remains routine in many institutions, this suggests that our results can be applied to a breadth of different surgical practices.
Another strength of our study is the utilization of institutional costs, and not patient charges or hospital reimbursements, as our outcomes metric. As the study patients were all treated at our institution, we were able to obtain the actual direct cost estimates for each patient, without the utilization of any cost estimation models. In order to demonstrate the broader applicability of our results beyond our specific institution, we converted all hospital costs to Medicare proportional dollars. Grenda et al 32 reviewed Medicare claims data for inpatient hospitals across the United States and demonstrated this cost metric to be a highly reliable measure of outcomes, allowing for comparison across varying hospital systems. Our study was not limited to Medicare patients so Medicare-adjusted dollars were used in place of Medicare claims data; however, the use of this standardized cost platform allows for greater generalizability of the cost-effectiveness of pasireotide in preventing POPF in a wide range of hospital settings.
CONCLUSION
Pasireotide administration during pancreatic resection significantly reduces the incidence of clinically significant postoperative pancreatic complications without increasing the overall cost of care. Pasireotide is a cost-effective intervention and should be strongly considered to be incorporated into the standard of care for pancreatic resections.
